Clinuvel compared to Imugene, page-35

Here is an example of just how severely undervalued Clinuvel is. Half the market cap compared to IMU which has all it's valuation on the 'hope' of future approval, receipts and profits. Clinuvel undervalued just on the current 'proof of concept' disease and with the mega indications to come which will be using the already FDA, TGA, EMA and Israel approved and Safe drug.

Imugene:
Cash Receipts last qtr: $0
Cash Receipts last 12 months $0
Net Cash used last qtr: $10.1M (loss)
Net Cash used last 12 months $30.9M (loss)
CASH ON HAND $100 MILLION enough for 9.8 qtrs funding according to section 8.5 in 4c
Market cap. 1.4 BILLION AUD

Clinuvel (CUV)
Cash Receipts last qtr: $24.1M
Cash Receipts last 12 months $66.4M (massive growth underway)
Net Cash last qtr: $18.5 (profit)
Net Cash last 12 months $39.9M (profit)
CASH ON HAND $121.5 MILLION with no debts
Market cap. 0.76 BILLION AUD

All IMO DYOR